MELBOURNE, AUSTRALIA--(Marketwire - August 31, 2009) - Antisense Therapeutics Limited
(PINKSHEETS: ATHJY) (ASX: ANP) today announced that the Company is
scheduled to present at the Rodman & Renshaw 11th Annual Global Healthcare
Conference, on September 9th-11th in New York City.
Mark Diamond, Antisense Therapeutics' Chief Executive Officer, will give a
presentation on Wednesday, September 9th at 10:25 a.m. EST in the Hubbard
Salon at the NY Palace Hotel. Mr. Diamond will provide an overview of the
Company's drug development pipeline with focus on the Company's lead
compound, ATL/TV1102 for Multiple Sclerosis (MS), which has been licensed
to Teva Pharmaceutical Industries. The presentation will be followed by a
question and answer session and a live webcast may be accessed at the
Company's website, www.antisense.com.au.
A replay of the presentation will be archived for 90 days after the
conference, at the same location. For more information about the Rodman &
Renshaw 11th Annual Healthcare Conference, please visit Rodman & Renshaw's
website at www.rodmanandrenshaw.com.
Antisense management will be available for meetings in New York on
September 9th and 10th.
In April 2009, at the American Academy of Neurology (AAN) 61st Annual
Meeting in Seattle, Washington, Antisense's presentation of the clinical
study results from its Phase II ATL/TV1102 MS study was selected as being
in the top 5 percent of abstracts judged to be the most critical new
research out of more than 2000 studies presented over the entire scientific
program of the meeting.
In the study, it was demonstrated that ATL/TV1102, a second-generation
antisense drug designed to specifically inhibit the production of VLA-4 (a
clinically validated target in MS), significantly reduced the number of new
active lesions in patients with relapsing remitting MS taking ATL/TV1102
for 8 weeks, compared to placebo.
About Antisense Therapeutics Limited
Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed
biopharmaceutical drug discovery and development company. Its mission is
to create, develop and commercialise antisense pharmaceuticals for large
unmet markets. ANP has two drugs in development and two drugs in
pre-clinical research. ATL1102 (injection) is in the advanced stages of a
Phase IIa trial as a potential treatment of multiple sclerosis. ATL1103 is
a second-generation antisense drug designed to lower blood IGF-I levels and
is entering preclinical development as a potential treatment for acromegaly
and vision disorders. ATL1102 (inhaled) is at the pre-clinical research
stage as a potential treatment for asthma. ATL1101 is a second-generation
antisense drug at the pre-clinical research stage being investigated as a
potential treatment for prostate cancer. ATL1102 has been licensed to Teva
Pharmaceutical Industries Ltd.